Definium Therapeutics (DFTX) EBITDA (2019 - 2026)
Definium Therapeutics (DFTX) reported EBITDA of -$77.4 million for Q1 2026, down 231.09% year-over-year from $59.0 million in Q1 2025, and down 53.64% on a QoQ basis from -$50.4 million in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of EBITDA data on file, last reported at -$77.4 million in Q1 2026.
- Quarterly EBITDA fell 231.09% year-over-year to -$77.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$237.5 million (down 205.84% YoY) and the FY2025 annual result came in at -$183.5 million, down 69.61% from the prior year.
- EBITDA declined to -$77.4 million in Q1 2026 per DFTX's latest filing, from -$50.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$5.0 million in Q4 2022 and bottomed at -$77.4 million in Q1 2026.
- The 5-year median for EBITDA is -$24.3 million (2023), against an average of -$30.7 million.
- The widest annual swing landed in 2024, when EBITDA surged 80.08%; it then plunged 629.71% in 2025.
- Tracing DFTX's EBITDA over 5 years: stood at -$5.0 million in 2022, then slumped by 384.12% to -$24.3 million in 2023, then slumped by 42.99% to -$34.7 million in 2024, then slumped by 44.93% to -$50.4 million in 2025, then plunged by 53.64% to -$77.4 million in 2026.
- Per Business Quant, the three latest DFTX EBITDA figures stand at -$77.4 million (Q1 2026), -$50.4 million (Q4 2025), and -$67.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -77.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.36 Mn |
| Dec 31, 2025 | -50.35 Mn |
| Sep 30, 2025 | -67.07 Mn |
| Jun 30, 2025 | -42.74 Mn |
| Mar 31, 2025 | -23.37 Mn |
| Dec 31, 2024 | -34.74 Mn |
| Sep 30, 2024 | -13.70 Mn |
| Jun 30, 2024 | -5.86 Mn |
| Mar 31, 2024 | -53.91 Mn |
| Dec 31, 2023 | -24.30 Mn |
| Sep 30, 2023 | -17.51 Mn |
| Jun 30, 2023 | -29.41 Mn |
| Mar 31, 2023 | -24.80 Mn |
| Dec 31, 2022 | -5.02 Mn |
| Sep 30, 2022 | -16.59 Mn |
| Jun 30, 2022 | -17.10 Mn |
| Mar 31, 2022 | -18.50 Mn |
| Dec 31, 2021 | -16.45 Mn |
| Sep 30, 2021 | -17.58 Mn |
| Jun 30, 2021 | -44.55 Mn |
| Mar 31, 2021 | -13.70 Mn |
| Dec 31, 2020 | 750,000.00 |
| Sep 30, 2020 | -8.68 Mn |
| Jun 30, 2020 | -5.72 Mn |
| Mar 31, 2020 | -7.02 Mn |
| Dec 31, 2019 | -10.70 Mn |